Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mike Grey
AddedMar 31, 2024
UpdatedMay 31, 2026
Mike Grey

Mike Grey

Board Member, Pappas Ventures

CrunchbaseLinkedIn

Mike Grey's Career

Pappas Ventures
Pappas Ventures

Durham, NC, US

Board Member· Board
Spruce Biosciences
Spruce Biosciences

South San Francisco, CA, US

Board Member· Board
Mirum Pharmaceuticals
Mirum Pharmaceuticals

Foster City, CA, US

Board Member· Board
Horizon Therapeutics
Horizon Therapeutics

Lake Forest, IL, US

Board Member· Board
Plexium
Plexium

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mike Grey's Career

Pappas Ventures
Pappas Ventures
331994Durham, NC, US
Board Member· Board
Spruce Biosciences
Spruce Biosciences
Public$161.6M472014South San Francisco, CA, US
Board Member· Board

Leadership at Spruce Biosciences

Dan SpiegelmanDan SpiegelmanBoard Member
Dr. Javier Szwarcberg M.D.Dr. Javier Szwarcberg M.D.Board Member
Alexis HowertonAlexis HowertonFounder
Camilla V. SimpsonCamilla V. SimpsonBoard Member
Tiba AynechiTiba AynechiBoard Member
Niall O'DonnellNiall O'DonnellBoard Member
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Public$497M1962018Foster City, CA, US
Board Member· Board

Leadership at Mirum Pharmaceuticals

Laura BregeLaura BregeBoard Member
Ed MathersEd MathersBoard Member
Patrick HeronPatrick HeronBoard Member
Chris PeetzChris PeetzBoard Member
Laurent FischerLaurent FischerBoard Member
Jonathan LeffJonathan LeffBoard Member

Similar to Mirum Pharmaceuticals

Intercept PharmaceuticalsIntercept PharmaceuticalsNew York City, NY, USPharmaceuticalsest. 2002Intercept PharmaceuticalsNew York City, NY, US · est. 2002

Intercept Pharmaceuticals: An American biopharma firm specializing in synthetic bile acid analogs for chronic liver diseases.

Public · $970M341
Mirata PharmaceuticalsMirata PharmaceuticalsPlymouth Meeting, PA, USPain Relief, Pharmaceuticalsest. 2017Mirata PharmaceuticalsPlymouth Meeting, PA, US · est. 2017

Mirata Pharmaceuticals: Innovating powerful, opioid-based pain relief solutions for patients and physicians.

Series A · $11M5
Catalyst PharmaceuticalsCatalyst PharmaceuticalsCoral Gables, FL, USPharmaceuticals, Therapiesest. 2002Catalyst PharmaceuticalsCoral Gables, FL, US · est. 2002

Catalyst Pharmaceuticals: A US-based biopharmaceutical firm developing therapies for debilitating diseases.

Public · $273.9M76
Bayer PharmaceuticalsBayer PharmaceuticalsBerlin, Berlin, DEDrugs, Pharmaceuticalsest. 2003Bayer PharmaceuticalsBerlin, Berlin, DE · est. 2003

Bayer Pharmaceuticals: A global enterprise specializing in biochemical research and drug manufacturing since 2008.

Public10k
Horizon Therapeutics
Horizon Therapeutics
Acquired02005Lake Forest, IL, US
Board Member· Board

Leadership at Horizon Therapeutics

Tim WalbertTim WalbertCEO
Rob HopfnerRob HopfnerBoard Member
Gino SantiniGino SantiniBoard Member
Mr. Timothy P. WalbertMr. Timothy P. WalbertBoard Member
Liam DanielLiam DanielBoard Member
Plexium
Plexium
Series B$165M942018San Diego, CA, US
Board Member· Board

Leadership at Plexium

Andrew MacConnellAndrew MacConnellCo-Founder
Brian WongBrian WongBoard Member
Kiersten SteadKiersten SteadBoard Member
Joe RokickiJoe RokickiCo-Founder
Tim KutzkeyTim KutzkeyBoard Member

Similar to Plexium

NurixNurixSan Francisco, CA, USDrugsest. 2012NurixSan Francisco, CA, US · est. 2012

San Francisco-based Nurix Therapeutics develops novel drugs, harnessing natural processes to treat cancer.

Public · $370.9M297
NeomorphNeomorphSan Diego, CA, USDrug Discoveryest. 2020NeomorphSan Diego, CA, US · est. 2020

Neomorph, a San Diego-based biotech firm, innovates new medicines to solve critical health issues.

Series A · $109M62
Differentiated TherapeuticsDifferentiated TherapeuticsBoston, MA, USTPD Therapiesest. 2021Differentiated TherapeuticsBoston, MA, US · est. 2021

Distinct Therapeutics designs and develops innovative TPD therapies for patients with unmet medical needs.

Seed · $5M6
BiotheryxBiotheryxSan Diego, CA, USBiopharmaceuticalsest. 2007BiotheryxSan Diego, CA, US · est. 2007

US-based BioTheryX: Developing therapies for hematological malignancies.

Public · $134.7M39

Mike Grey's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Mike Grey

Mike GiardelloMike GiardelloCo-Founder · Mount Wilson VenturesDean GrayDean GrayBoard Member · National Renewable Energy LaboratoryNeil ExterNeil ExterBoard Member · New England Venture Capital AssociationJarrett LilienJarrett LilienFounder · Bendigo PartnersAnthony ShuberAnthony ShuberFounder · Exact SciencesMike AicherMike AicherBoard Member · Roswell Biotechnologies